TGTX
TGTX
NASDAQ · Biotechnology

Tg Therapeutics Inc

$53.94
-0.46 (-0.85%)
Financial Highlights (FY 2026)
Revenue
584.49M
Net Income
424.10M
Gross Margin
83.7%
Profit Margin
72.6%
Rev Growth
+504.9%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 584.49M 1.04B 1.08B 956.87M
Gross Profit 488.98M 701.79M 727.04M 646.94M
Operating Income 116.96M 118.01M 120.46M 122.04M
Net Income 424.10M 129.57M 136.18M 105.42M
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Rev Growth +504.9% +16.6% +24.3% +11.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.13B 908.15M 880.79M 975.86M
Total Equity 1.94B 2.79B 2.78B 2.56B
D/E Ratio 1.10 0.33 0.32 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 117.02M 169.61M 170.48M 149.89M
Free Cash Flow 110.01M 140.89M 136.27M